PMID- 28477447
OWN - NLM
STAT- MEDLINE
DCOM- 20180323
LR  - 20220410
IS  - 1873-3360 (Electronic)
IS  - 0306-4530 (Linking)
VI  - 81
DP  - 2017 Jul
TI  - Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible 
      relationship between BDNF and TNF-alpha.
PG  - 138-143
LID - S0306-4530(17)30253-6 [pii]
LID - 10.1016/j.psyneuen.2017.04.014 [doi]
AB  - OBJECTIVE: There is accumulating evidence indicating that long-term treatment 
      with second-generation antipsychotics (SGAs) results in metabolic syndrome (MetS) 
      and cognitive impairment. This evidence suggests an intrinsic link between 
      antipsychotic-induced MetS and cognitive dysfunction in schizophrenia patients. 
      Olanzapine is a commonly prescribed SGA with a significantly higher MetS risk 
      than that of most antipsychotics. In this study, we hypothesized that 
      olanzapine-induced MetS may exacerbate cognitive dysfunction in patients with 
      schizophrenia. METHODS: A sample of 216 schizophrenia patients receiving 
      long-term olanzapine monotherapy were divided into two groups, MetS and non-MetS, 
      based on the diagnostic criteria of the National Cholesterol Education Program's 
      Adult Treatment Panel III. We also recruited 72 healthy individuals for a control 
      group. Cognitive function was evaluated using the Repeatable Battery for the 
      Assessment of Neuropsychological Status (RBANS). Plasma brain-derived 
      neurotrophic factor (BDNF) and tumor necrosis factor-alpha (TNF-alpha) were 
      measured by an enzyme-linked immunosorbent assay for 108 patients and 47 
      controls. RESULTS: Among the 216 schizophrenia patients receiving olanzapine 
      monotherapy, MetS was found in 95/216 (44%). Patients with MetS had more negative 
      symptoms, higher total scores in PANSS (Ps<0.05) and lower immediate memory, 
      attention, delayed memory and total scores in RBANS (Ps<0.01). Stepwise 
      multivariate linear regression analysis revealed that increased glucose was the 
      independent risk factor for cognitive dysfunction (t=-2.57, P=0.01). Patients 
      with MetS had significantly lower BDNF (F=6.49, P=0.012) and higher TNF-alpha 
      (F=5.08, P=0.026) levels than those without MetS. There was a negative 
      correlation between the BDNF and TNF-alpha levels in the patients (r=-0.196, 
      P=0.042). CONCLUSION: Our findings provide evidence suggesting that the metabolic 
      adverse effects of olanzapine may aggravate cognitive dysfunction in patients 
      with schizophrenia through an interaction between BDNF and TNF-alpha.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Zhang, Chen
AU  - Zhang C
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China. Electronic address: 
      zhangchen645@gmail.com.
FAU - Fang, Xinyu
AU  - Fang X
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Yao, Peifen
AU  - Yao P
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Mao, Yemeng
AU  - Mao Y
AD  - Department of Pharmacology, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Cai, Jun
AU  - Cai J
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Chen, Meijuan
AU  - Chen M
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Fan, Weixing
AU  - Fan W
AD  - Department of Psychiatry, Jinhua Second Hospital, Jinhua, Zhejiang, China.
FAU - Tang, Wei
AU  - Tang W
AD  - Department of Psychiatry, Wenzhou Kanging Hospital, Wenzhou, Zhejiang, China.
FAU - Song, Lisheng
AU  - Song L
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China. Electronic address: 
      slslulu@163.com.
LA  - eng
PT  - Journal Article
DEP - 20170427
PL  - England
TA  - Psychoneuroendocrinology
JT  - Psychoneuroendocrinology
JID - 7612148
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/adverse effects/therapeutic use
MH  - Benzodiazepines/*adverse effects/metabolism/therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Case-Control Studies
MH  - Cognitive Dysfunction/blood/*chemically induced/complications
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolic Syndrome/blood/*chemically induced/complications
MH  - Olanzapine
MH  - Schizophrenia/blood/drug therapy
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*blood
MH  - Young Adult
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor
OT  - Cognitive function
OT  - Metabolic syndrome
OT  - Olanzapine
OT  - Tumor necrosis factor-alpha
EDAT- 2017/05/10 06:00
MHDA- 2018/03/24 06:00
CRDT- 2017/05/07 06:00
PHST- 2017/03/13 00:00 [received]
PHST- 2017/04/17 00:00 [revised]
PHST- 2017/04/21 00:00 [accepted]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2018/03/24 06:00 [medline]
PHST- 2017/05/07 06:00 [entrez]
AID - S0306-4530(17)30253-6 [pii]
AID - 10.1016/j.psyneuen.2017.04.014 [doi]
PST - ppublish
SO  - Psychoneuroendocrinology. 2017 Jul;81:138-143. doi: 
      10.1016/j.psyneuen.2017.04.014. Epub 2017 Apr 27.